Figure 2
Figure 2. Phenotype analysis of lymphomas from HTLV-1-HU-NOD/SCID and Tax1-HU-NOD/SCID mice. Phenotype analysis of lymphocytes from the MLN (A,E,I,L) and the spleen (B,F,J,M) of HTLV-1-HU-NOD/SCID mouse (#7762, 16 weeks after injection) and MLN of Tax1-HU-NOD/SCID (#7749, 14 weeks after injection) mouse (C,G,K,N). Human CD3+ cells are gated and analyzed in panels I, J, and K. CD4+/CD8− are the predominant populations in HTLV-1-HU-NOD/SCID mice MLN (I) and spleen (J) and Tax1-HU-NOD/SCID mice MLN (K). Human lymphocytes in the mesenteric lymph nodes (D) of mock-infected donor-tissue matched HU-NOD/SCID (#7762, 16 weeks after injection) mice are predominantly of CD19+ (B-cell) lineage (H). HTLV-1 p19gag expression in CD4+ T cells from the MLN (L) and spleen (M) of the HTLV-1-HU-NOD/SCID mouse. Expression of GFP in the CD4+ T cells from (N) the MLN of the Tax1-HU-NOD/SCID mouse and (O) in cells from the MLN of mock-infected mouse. (P) Proliferation of CD4+/CD8− subpopulation among gated human lymphocytes in the thymus of the HTLV-1-HU-NOD/SCID mouse (#7241, 9 weeks after injection; iii) in comparison with mock HU-NOD/SCID mouse (#7241, 8 weeks after injection; ii). Comparative Giemsa staining of lymphoma cells derived from HTLV-1-HU-NOD/SCID mouse (Q) and RV-ATL tumor cell line (R).28

Phenotype analysis of lymphomas from HTLV-1-HU-NOD/SCID and Tax1-HU-NOD/SCID mice. Phenotype analysis of lymphocytes from the MLN (A,E,I,L) and the spleen (B,F,J,M) of HTLV-1-HU-NOD/SCID mouse (#7762, 16 weeks after injection) and MLN of Tax1-HU-NOD/SCID (#7749, 14 weeks after injection) mouse (C,G,K,N). Human CD3+ cells are gated and analyzed in panels I, J, and K. CD4+/CD8 are the predominant populations in HTLV-1-HU-NOD/SCID mice MLN (I) and spleen (J) and Tax1-HU-NOD/SCID mice MLN (K). Human lymphocytes in the mesenteric lymph nodes (D) of mock-infected donor-tissue matched HU-NOD/SCID (#7762, 16 weeks after injection) mice are predominantly of CD19+ (B-cell) lineage (H). HTLV-1 p19gag expression in CD4+ T cells from the MLN (L) and spleen (M) of the HTLV-1-HU-NOD/SCID mouse. Expression of GFP in the CD4+ T cells from (N) the MLN of the Tax1-HU-NOD/SCID mouse and (O) in cells from the MLN of mock-infected mouse. (P) Proliferation of CD4+/CD8 subpopulation among gated human lymphocytes in the thymus of the HTLV-1-HU-NOD/SCID mouse (#7241, 9 weeks after injection; iii) in comparison with mock HU-NOD/SCID mouse (#7241, 8 weeks after injection; ii). Comparative Giemsa staining of lymphoma cells derived from HTLV-1-HU-NOD/SCID mouse (Q) and RV-ATL tumor cell line (R).28 

Close Modal

or Create an Account

Close Modal
Close Modal